Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Barinthus Biotherapeutics plc - American Depositary Shares (BRNS)
Company Research
Source: PR Newswire
The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and development of innovative interferon therapies are key factors fueling the expansion of the interferon market from 2025 to 2032.LAS VEGAS, March 5, 2025 /PRNewswire/ -- DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading interferons companies' market shares, challenges, interferons market drivers, barriers, trends, and key market interferons companies in the market.Key Takeaways from the Interferons Market ReportAs per DelveInsight estimates, North America is anticipated to dominate the global interferons market during the forecast period. In the application segment of the interferon market, the leukemia category captured a significant revenue share in 2024.Notable interferons companies such as Bayer AG, Amega Biotech, Biogen, M
Show less
Read more
Impact Snapshot
Event Time:
BRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRNS alerts
High impacting Barinthus Biotherapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BRNS
News
- Barinthus Biotherapeutics (NASDAQ:BRNS) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseGlobeNewswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITBPR Newswire
- Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate DevelopmentsGlobeNewswire
BRNS
Earnings
- 5/7/25 - Miss
BRNS
Sec Filings
- 12/10/25 - Form 8-K
- 11/7/25 - Form 10-Q
- 11/7/25 - Form 8-K
- BRNS's page on the SEC website